Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment

As the mainstay treatment for advanced prostate cancer, androgen deprivation therapy (ADT) targets the action of androgen receptor (AR) by reducing androgen level and/or by using anti-androgen to compete with androgens for binding to AR. Albeit effective in extending survival, ADT is associated with dose-limiting toxicity and the development of castration-resistant prostate cancer (CRPC) after prolonged use. Because CRPC is lethal and incurable, developing effective strategies to enhance the efficacy of ADT and circumvent resistance becomes an urgent task. Continuous AR signaling constitutes one major mechanism underlying the development of CRPC. The present study showed that methylseleninic acid (MSA), an agent that effectively reduces AR abundance, could enhance the cancer-killing efficacy of the anti-androgen bicalutamide in androgen-dependent and CRPC cells. We found that the combination of MSA and bicalutamide produced a robust downregulation of prostate-specific antigen and a recently identified AR target, telomerase, and its catalytic subunit, human telomerase reverse transcriptase. The downregulation of hTERT occurs mainly at the transcriptional level, and reduced AR occupancy of the promoter contributes to downregulation. Furthermore, apoptosis induction by the two agents is significantly mitigated by the restoration of hTERT. Our findings thus indicate that MSA in combination with anti-androgen could represent a viable approach to improve the therapeutic outcome of ADT. Given the critical role of hTERT/telomerase downregulation in mediating the combination effect and the fact that hTERT/telomerase could be measured in blood and urine, hTERT/telomerase could serve as an ideal tumor-specific biomarker to monitor the efficacy of the combination therapy noninvasively. Mol Cancer Ther; 9(7); 2016–25. ©2010 AACR.

[1]  H. Klocker,et al.  Expression, structure, and function of androgen receptor in advanced prostatic carcinoma , 1998, The Prostate.

[2]  Ina Prade,et al.  Wild‐type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Yue Wu,et al.  Endoplasmic reticulum stress signal mediators are targets of selenium action. , 2005, Cancer research.

[4]  Yue Wu,et al.  Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells , 2006, Molecular Cancer Therapeutics.

[5]  C. Counter,et al.  Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. , 2001, The Journal of urology.

[6]  C. Ip,et al.  Lessons from basic research in selenium and cancer prevention. , 1998, The Journal of nutrition.

[7]  E. Blackburn,et al.  Telomere states and cell fates , 2000, Nature.

[8]  E. Blackburn,et al.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis , 1989, Nature.

[9]  Cheng Jiang,et al.  Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. , 2001, Cancer research.

[10]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[11]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[12]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[13]  H. Ganther,et al.  In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. , 2000, Cancer research.

[14]  C. Harley,et al.  Telomerase, cell immortality, and cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.

[15]  W. Willett,et al.  A prospective study of plasma selenium levels and prostate cancer risk. , 2004, Journal of the National Cancer Institute.

[16]  Mike Wilson,et al.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Clement Ip,et al.  Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers , 2005, Molecular Cancer Therapeutics.

[18]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[19]  E. Meuillet,et al.  Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings , 2004, Journal of cellular biochemistry.

[20]  E. Appella,et al.  Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. , 2002, Molecular biology of the cell.

[21]  G. Combs,et al.  Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. , 2008, Carcinogenesis.

[22]  P. Rennie,et al.  Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. , 2006, Cancer research.

[23]  C. Ip,et al.  Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling , 2004, Cancer Research.

[24]  G. Combs,et al.  Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin , 2008, Clinical Cancer Research.

[25]  Sung-Dae Cho,et al.  Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. , 2004, Molecular cancer therapeutics.

[26]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[27]  L. Clark,et al.  A report of high-dose selenium supplementation: response and toxicities. , 2004, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[28]  S. Aliño,et al.  Real‐Time Quantification of Human Telomerase Reverse Transcriptase mRNA in the Plasma of Patients with Prostate Cancer , 2006, Annals of the New York Academy of Sciences.

[29]  G. R. Stevens,et al.  Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT , 2004, Cancer.

[30]  G. Botchkina,et al.  Noninvasive Detection of Prostate Cancer by Quantitative Analysis of Telomerase Activity , 2005, Clinical Cancer Research.

[31]  R. Ravazzolo,et al.  Nuclear run-on assay using biotin labeling, magnetic bead capture and analysis by fluorescence-based RT-PCR. , 2000, BioTechniques.

[32]  G. Mills,et al.  Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. , 1993, Cancer research.

[33]  B. Armbruster,et al.  In vivo regulation of hTERT expression and telomerase activity by androgen. , 2003, The Journal of urology.

[34]  J. Crowley,et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.

[35]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[36]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[37]  Cheng Jiang,et al.  Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. , 2002, Molecular cancer therapeutics.

[38]  D. Trump,et al.  Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate‐specific antigen (PSA) , 2006, The Prostate.

[39]  Y. Kondo,et al.  Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component , 2000, Oncogene.

[40]  Hongbo Hu,et al.  Methyl-Selenium Compounds Inhibit Prostate Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model with Survival Benefit , 2009, Cancer Prevention Research.

[41]  S. Hirano,et al.  Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of selenomethionine and methylselenocysteine to rats. , 2009, Chemical research in toxicology.

[42]  L. Hawthorn,et al.  Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. , 2003, Cancer research.

[43]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[44]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[45]  M. Blasco.  Telomerase beyond telomeres , 2002, Nature Reviews Cancer.

[46]  A. Schönthal,et al.  Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines* , 1998, The Journal of Biological Chemistry.

[47]  Y. Dong,et al.  Krüppel-Like Factor 4 Is a Novel Mediator of Selenium in Growth Inhibition , 2008, Molecular Cancer Research.

[48]  C. Wittwer,et al.  Nuclear Run-On Assay Using Biotin Labeling , Magnetic Bead Capture and Analysis by Fluorescence-Based RT-PCR , 2001 .

[49]  L. Klotz,et al.  Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. , 1998, Cancer research.

[50]  M. Gleave,et al.  In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors , 2009, Clinical Cancer Research.